Letter to the Editor: Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy—Insights and Perspectives

Clinical Therapeutics 2026

View at publisher

Authors: Yi Cai

DOI: 10.1016/j.clinthera.2026.01.008

Cited by: 1

References: 1

Fields of Study & Subjects

Antiplatelet Therapy and Cardiovascular Diseases Pharmacogenetics and Drug Metabolism Eicosanoids and Hypertension Pharmacology

References 1